Teva presents at the 7th Annual Evercore ISI HealthCONx Conference | 26.11.24

TEL AVIV, Israel, November 25, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, and Eric Hughes, Teva’s Executive Vice President of Global R&D and Chief Medical Officer, will attend the 7^e Annual Evercore ISI HealthCONx Conference on Thursday, December 5, 2024. Presentation begins at 8:20 AM Eastern Time.

To access a live webcast of the presentation, please visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.

An archived version of the webcast will be available within 24 hours of the end of the live discussion.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, leveraging our generics expertise and accelerating innovation to continue the momentum behind the discovery, delivery and comprehensive development of modern medicines. For more than 120 years, Teva’s commitment to improving health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees in 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve the health outcomes of millions of patients every day. To learn more about how Teva is committed to better health, visit www.tevapharm.com.

Cautionary Statement Regarding Forward-Looking Statements

This document and the conference presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to significant risks and uncertainties, both known and unknown . which could cause our future results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks related to: our ability to compete successfully in the marketplace, including our ability to successfully execute our Pivot to Growth strategy, including expanding of our innovative and biosimilar medicines pipeline and profitably commercializing the innovative medicines and biosimilar portfolio, both organically and through business development, and to maintain and concentrate our generic medicines portfolio; our significant indebtedness; our operations and activities generally, including the impact of global economic conditions and other macroeconomic developments and governmental and societal responses thereto; compliance, regulation and litigation; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections entitled “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise cautioned not to unduly to rely on these forward-looking statements.